Mirabegron Teva Uk (Mirabegron)

Mirabegron acts on the β3‑adrenergic pathway to improve bladder storage function in patients with overactive bladder.

• Overactive bladder: increases bladder capacity and reduces urgency episodes.
• Urinary urgency: lessens the sudden need to void.
• Urinary frequency: decreases the number of daily voids.

• Mirabegron activates β3‑adrenergic receptors located in the detrusor smooth muscle of the bladder. Receptor activation stimulates cyclic AMP production, leading to relaxation of the detrusor muscle during the storage phase, thereby increasing functional bladder capacity and reducing involuntary contractions that cause urgency and frequency.

Common Side Effects

• Hypertension: elevated blood pressure may be observed.
• Nasopharyngitis: mild upper respiratory tract infection symptoms.
• Headache: occasional mild to moderate headache.
• Constipation: reduced bowel motility.
• Dry mouth: decreased salivation.
• Urinary retention: difficulty initiating urination.

Serious or Rare Side Effects

• Severe hypertension: marked increase in blood pressure requiring medical attention.
• Angioedema: swelling of face, lips, tongue, or throat.
• Tachycardia: rapid heart rate.
• Acute urinary retention: inability to void, may need catheterization.
• Allergic reactions: rash, pruritus, or anaphylaxis.
• Renal impairment: worsening kidney function in susceptible individuals.

Before initiating therapy, clinicians should evaluate patient-specific factors and monitor for adverse events.

• Assess blood pressure: ensure baseline control before starting.
• Monitor urinary retention: watch for signs of incomplete bladder emptying.
• Review renal function: adjust use in patients with impaired kidneys.
• Evaluate hepatic status: consider dose modification if liver disease is present.
• Avoid use in uncontrolled hypertension: risk of exacerbation.
• Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Mirabegron may alter the pharmacokinetics of co‑administered medicines and vice versa.

Major Interactions (Avoid)

• Strong CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): increase mirabegron exposure.
• Potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): raise plasma levels.
• Anticholinergic agents: may exacerbate urinary retention.

Moderate Interactions (Monitor Closely)

• Moderate CYP2D6 inhibitors (e.g., duloxetine): require dose adjustment.
• CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce efficacy.
• Antihypertensives: monitor blood pressure for additive effects.
• Diuretics: watch for fluid‑electrolyte shifts.
• NSAIDs: may increase risk of hypertension.